Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma

Cancer

Volumn 83, Issue 5, 1998, Pages 851-857

  Ng, Irene O L ^a   Lam, King Y ^a   Ng, Matthew ^b   Kwong, Dora L W ^a   Sham, Jonathan S T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b TUNG WAH HOSPITAL   (Hong Kong)

Author keywords

Multidrug resistance; Oral cancers; P glycoprotein; p53; Radiation

Indexed keywords

GENE PRODUCT; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; P-GLYCOPROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032169043     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980901)83:5<851::AID-CNCR8>3.0.CO;2-L     Document Type: Article

References (23)

1. Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol 1989;16:156-65.
2. McClean S, Hosking LK, Hill BT. Dominant expression of multiple drug resistance after in vitro X-irradiation exposure in intraspecific Chinese hamster ovary hybrid cells. J Natl Cancer Inst 1993;85:48-53.
3. Hill BT, Whelan RD, Hurst HC, McClean S. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated C-irradiation. Cancer 1994;73:2990-9.
4. Rao RS, Parikh DM, Parikh HK, Bhansali MB, Deshmane VH, Fakih AR. Perioperative chemotherapy in patients with oral cancer. Am J Surg 1994;168:262-7.
5. Shaw HI, Price LA, Hill BT, Calvert AH, Dalley VM, Levene A. A randomized combination chemotherapy trial, with and without adriamycin, in squamous cell carcinoma of the head and neck. Otolaryngology 1978;86:845-50.
6. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
7. Zastawny RL, Salvino R, Chen IM, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993;8:1529-35.
8. Hsu IC, Metcalf RA, Sun T, Welsh IA, Wang NI, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
9. Wahi PN, Cohen B, Luthra UK, Torloni H. Histological typing of oral and oropharyngeal tumours. In: International histological classification of tumours. Geneva: World Health Organization, 1971:17-8.
10. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch IF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
11. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. Identification of members of P-glycoprotein multigene family. Mol Cell Biol 1989;9:1224-32.
12. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene specific monoclonal antibodies. Proc Natl Acad Sci USA 1990;87:152-6.
13. Cortes EP, Kalra J, Amin VC, Attie J, Eisenbud L, Khafif R, et al. Chemotherapy for head and neck cancer relapsing after radiotherapy. Cancer 1981;47:1966-70.
14. Hill BT, Deuchars K, Hosking LK, Ling V, Whelan RDH. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst 1990;82:607-12.
15. Stammler G, Pommerenke EW, Mattern J, Volm M. Effects of single doses of irradiation on the expression of resistance-related proteins in murine NIH 3T3 and human lung carcinoma cells. Carcinogenesis 1995;16:2051-5.
16. Nylander K, Nilsson P, Mehle C, Roos G. p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. Br J Cancer 1995;71:826-30.
17. Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1996; 88:1228-33.
18. Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, et al. Immunohistochemical vs molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11.
19. Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-29.
20. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
21. de Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307-11.
22. Soini Y, Virkajarvi N, Raunio H, Paakko P. Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol 1996;49:470-3.
23. Schneider I, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86:850-5.